Patients in the HeartMate II DT trial were randomized to the HeartMate II or the HeartMate® XVE--the only other device approved for DT--on a 2:1 basis, respectively.

Thoratec is saying it has received approval of a PMA supplement for use of its HeartMate XVE left ventricle assist system for destination therapy from the Food and Drug Administration. The company ...

The actuarial survival rates at two years were 58% and 24% for the HeartMate II and HeartMate XVE, respectively (p=0.008). Of the 134 patients randomized to HeartMate II, 62 survived at least two ...

Mon, 07 Apr 2003 22:15:00 Pleasanton, CA - The FDA has approved Thoratec's new, improved HeartMate® XVE left ventricular assist system (LVAS) for destination therapy in end-stage heart failure ...

Having long searched for suitable machines to replace the beating heart, physicians now have cause for optimism after tests of a new generation of pumps that continuously spin blood throughout the ...

WASHINGTON -- The U.S. Food and Drug Administration Monday approved a new type of heart-pumping device from Thoratec Corp. designed to support heart patients who are awaiting transplants. The FDA ...

Thoratec Corporation’s HeartMate II LV assist system, a continuous-flow LV assist pump based on the design of an earlier and larger HeartMate XVE pulsatile device, received a unanimous ...

Thoratec Corp. has won crucial approval from the Food and Drug Administration to market a little heart pump that could push its 2008 sales as high as $265 million, up 13 percent from 2007, while ...

The incidence of internal bleeding was higher in the HeartMate II left ventricular assist device than the earlier HeartMate I XVE, according to two recent studies. Although there were more ...

The University of Pittsburgh Medical Center (UPMC) is discharging its first patient who was successfully implanted, on July 2, with the Heartmate XVE™ Left Ventricular Assist System (LVAS). It ...

Advanced heart failure patients receiving a new type of heart pump made by Thoratec Corp <THOR.O> lived longer and fared far better than patients getting the company's older HeartMate XVE device ...